Document:

exv10w28

 

Exhibit 10.28

EXECUTION COPY

RXI PHARMACEUTICALS CORPORATION

SCIENTIFIC ADVISORY BOARD AGREEMENT

     This
Scientific Advisory Board Agreement (the
“Agreement”) dated as of February 26,
2007, is made by Craig C. Mello, Ph.D. (the “SAB Member”) and RXi Pharmaceuticals
Corporation, a Delaware corporation (“RXi” and together with the SAB Member, the
“Parties”). The SAB Member is an investigator of the Howard Hughes Medical Institute (the
“Institute”) at the Institute’s laboratory at the University of Massachusetts.

AGREEMENT

	 	1.	 	General.

               (A) Effective Date. Subject to the terms and conditions of this Agreement, this Agreement
will become effective upon the completion of all the following events:

	 	(1)	 	the execution of this Agreement by the Parties;
	 
	 	(2)	 	the approval of this Agreement by each Principal Institution (defined
below);
	 
	 	(3)	 	the execution of Schedule A hereto by all parties thereto;
	 
	 	(4)	 	the transfer to RXi of substantially all of the
RNAi assets owned or controlled by CytRx Corporation (“CytRx”); and
	 
	 	(5)	 	the closing of an equity financing of RXi or
its successor in an aggregate amount of not less than $15 million
dollars or such lesser dollar amount as RXi accepts as an initial
investment from investors (including CytRx acting as an Investor) (the
“Equity Funding”).

The date wherein all of these events are completed (the “Effective Date”) will be indicated
below the signature of the SAB Member on the signature page of this Agreement. If the Effective
Date has not occurred by June 30, 2007, then this Agreement and its terms will be null and void
unless the Parties mutually agree otherwise.

               (B) Services. As of the Effective Date, RXi shall retain the SAB Member, and the SAB Member
agrees to serve, as a member of RXi’s Scientific Advisory Board (“SAB”) and to consult with
RXi in the Field (as hereinafter defined). The SAB Member agrees to provide to RXi such services
in the Field as are customarily performed by a member of a scientific advisory board to a company
such as RXi (the “Services”). The SAB Member is being engaged by RXi as a consultant for
the exchange of ideas only and shall not direct or conduct research for or on behalf of RXi. The
Services will include, without limitation:

 

 

	 	•	 	Consulting with RXi’s respective management within the SAB Member’s professional
area of expertise from time to time as reasonably requested by RXi;
	 
	 	•	 	Exchanging strategic and business development ideas with RXi;
	 
	 	•	 	Attending scientific, medical or business meetings with RXi’s management, such as
United States Food & Drug Administration meetings, meetings with strategic or potential
strategic partners and other meetings relevant to SAB Member’s area of expertise; and
	 
	 	•	 	Attending meetings of the SAB as provided herein.

     For purposes of this Agreement, the term “Field” means the use of RNAi technology in,
or the application of RNAi technology to, the discovery or development of therapeutic products for
humans or animals, and/or the use of RNAi as a component of therapeutic products for humans or
animals. Notwithstanding anything else herein to the contrary, the term “Field” is specifically
understood to not include the use of RNAi technology in, or the application of RNAi
technology to, the discovery and development of reagents, diagnostic products, agricultural
products, or products or services developed for or offered to the research tools and products
market, or the use of RNAi as a component of reagents, diagnostic products, agricultural products,
or products or services developed for or offered to the research tools and products market. The
Services shall not include those services prohibited by either Principal Institution, including as
set forth in “The University of Massachusetts Uniform Consulting Agreement Provisions” attached
hereto as Exhibit A and incorporated herein (the “UMass Provisions”) or any Affiliated
Institution (as defined in Section 2 hereof). The SAB Member is agreeing to provide the Services
under this Agreement in consideration of the compensation provided in Section 3 hereof.

     2. Performance of Services. As of the Effective Date, the SAB Member agrees to make
himself available to render the Services, at such time or times and location or locations as may be
mutually agreed, from time to time at the request of RXi and subject to the UMass Provisions. The
SAB Member agrees not to perform any Services for RXi on the premises of the University of
Massachusetts Medical School (which, together with the Institute, are collectively referred to as
the “Principal Institution”), any academic institution or any hospital with which he is or
may become affiliated (each such Principal Institution, academic institution and hospital an
“Affiliated Institution”) or with the respective facilities or funds of any such Affiliated
Institution which could result in claims by such Affiliated Institution of rights in any Inventions
(as defined in Section 8 hereof), without the express prior agreement of RXi and the Affiliated
Institution, as appropriate. Unless covered by an appropriate agreement between any third party
(other than an Affiliated Institution) and RXi, the SAB Member shall not knowingly engage in any
activities or use any facilities in the course of providing Services which could result in claims
of ownership to any Inventions being made by such third party. The SAB Member agrees to devote his
reasonable and diligent efforts to the performance of the Services. The SAB Member agrees to
devote up to 20 days per year to providing the Services, including by attending at least 8 SAB
meetings per year.

-2-

 

	 	3.	 	Compensation.

               (A) Up-Front Cash Payment and Grant of Option. RXi will compensate the SAB Member for serving
as a member of the SAB and for providing the Services to RXi as follows, with such compensation to
be the full consideration for the Services:

(1) Commencing on the Effective Date, RXi shall pay the SAB Member a total
monthly payment of $5,000 for each month during the Term, payable monthly in
arrears as full payment for the cash portion of the SAB Member’s
compensation.

(2) RXi or, if applicable, its successor entity (the “Granting
Party”), shall, at the first regularly scheduled meeting of the Granting
Party following the Effective Date grant the SAB Member a nonqualified stock
option (the “Option”) under the standard option plan of the Granting
Party (the “Option Plan”) to purchase a number of shares of common
stock of RXi equal to 1/140th of the number of shares of common stock of RXi
held by CytRx immediately prior to the Equity Funding (the “Option
Shares”). If the value of the Granting Party’s common stock is not then
Publicly Available (as defined below), at the first regularly scheduled
Board meeting of the Granting Party following each of the first, second and
third anniversaries of the Effective Date, and otherwise on the first,
second and third anniversaries of the Effective Date, the Granting Party
will grant the SAB Member an additional Option to purchase the same number
of Option Shares as previously granted at the first regularly scheduled
Board meeting following the Effective Date. The Option granted at the first
Board meeting following the Effective Date shall have a per share exercise
price equal to the per share price paid for RXi stock in the Equity Funding.
Each additional Option granted pursuant to this Section shall have a per
share exercise price equal to the fair market value of the Granting Party’s
common stock on the respective date of each grant. If the Granting Party’s
common stock is Publicly Available on the date of such grant, the fair
market value shall be equal to the closing price of such stock on such
public market the date of such grant; if the Granting Party’s common stock
is not Publicly Available on the date of such grant, the fair market value
shall be determined in good faith by the Board of Directors of the Granting
Party. The Options shall be fully vested on the date of grant, shall have a
term of ten years, and shall otherwise be in the form of the standard
Nonqualified Stock Option Agreement used by the Granting Party in its Option
Plan. Notwithstanding any language in the standard Nonqualified Stock
Option Agreement or any other Granting Party document or agreement to the
contrary, the Options granted to the SAB Member hereunder shall not be
subject to lapse for any reason prior to the end of their ten year term.
The Granting Party covenants and agrees that it will file an effective Form
S-8 registration statement covering the Options and the Options Shares as
promptly as practicable after the Granting Party becomes eligible to file
such Form, such that from and after the date of

-3-

 

filing the Option Shares shall be freely tradable immediately upon any
exercise of the Options. The Options may be exercised pursuant to a
cashless exercise, but only if the SAB Member is not able at the time to
obtain the cash proceeds for the exercise price in a broker’s transaction
(with the Granting Party bearing any commission expenses charged by the
broker in connection with selling sufficient shares to generate the cash
proceeds for the exercise price). For purposes of this Agreement, the term
“Publicly Available” shall mean (i) the common stock of the Granting Company
is listed on a national securities exchange or admitted to unlisted trading
privileges on such exchange or (ii) the common stock is not so listed or
admitted to unlisted trading privileges, but is traded on the Nasdaq
SmallCap Market or the OTC Bulletin Board.

               (B) Equity Ownership Limit. To RXi’s best knowledge, after reasonable inquiry, the stock
options set forth herein, when added to all other stock, stock options, rights or other equity or
equity-based securities (collectively, “Securities”) issued or issuable by RXi to the SAB
Member (either directly or indirectly), constitute not more than 5.0% of RXi’s presently issued and
outstanding common stock, as diluted by assuming full exercise of any options and other rights held
by the SAB Member. Indirect holdings for this purpose include without limitation (i) any
Securities issued or issuable by RXi to members of the SAB Member’s immediate family and (ii) any
Securities issued or issuable by RXi to the SAB Member, or Securities allocated or allocable to the
SAB Member under the University of Massachusetts’ inventorship policies, as royalties under a
license by RXi of technology of which the SAB Member is an inventor.

               (C) Expenses. RXi also shall promptly reimburse the SAB Member for reasonable out-of-pocket
expenses, including, without limitation, travel expenses incurred by him in the performance of the
Services (including attendance at all SAB meetings), following RXi’s receipt of a request for
reimbursement from the SAB Member. The SAB Member shall promptly provide RXi with documentation
supporting all such expenses.

     4. Principal Institution. RXi recognizes that the activities of the SAB Member are or
will be subject to the rules and regulations of each Principal Institution and any other Affiliated
Institution, now or in the future, and RXi agrees that SAB Member shall be under no obligation to
perform Services if such performance would conflict with such rules and regulations, or constitute
a conflict of interest under the relevant policies of the Affiliated Institution. RXi further
acknowledges that the SAB Member is an employee of the Institute and is subject to the Institute’s
policies concerning consulting, conflicts of interest and intellectual property. RXi agrees that
nothing in this Agreement shall affect the SAB Member’s obligations to, or research on behalf of,
the Institute or the University of Massachusetts, including, without limitation, obligations or
research of the SAB Member in connection with a transfer by the Institute or the University of
Massachusetts of materials or intellectual property developed in whole or in part by the SAB
Member, or in connection with research collaborations. The SAB Member has no reason to believe
that the SAB Member’s performance of any of the services contemplated by this Agreement will
conflict with the applicable rules or policies of any Affiliated Institution, each as presently in
effect. In the event such rules and regulations shall, in RXi’s reasonable opinion or the
reasonable opinion of the SAB Member, substantially interfere

-4-

 

with the performance of Services by the SAB Member, RXi or the SAB Member may terminate this
Agreement upon 30 days notice to the other parties. Any such termination by RXi shall not be
considered a termination for Cause, unless the Affiliated Institution’s rules or policies that are
asserted by RXi or the SAB Member to be in conflict with the performance of the Services are rules
or policies that are not generally applied by that Affiliated Institution to other academic
researchers at that institution. The SAB Member shall provide copies to RXi of all status reports
he delivers and other material correspondences he has with any Affiliated Institution (other than
the Institute) concerning this Agreement or the Services within three (3) business days of his
delivery or receipt of such report or correspondence, provided that the policies of any Affiliated
Institution permit him to do so, and provided further that RXi agrees to hold any such report or
correspondence in confidence.

     5. Term. The SAB Member’s performance of Services shall commence on the Effective
Date and shall continue for a period of four (4) years thereafter (such period, including any
extension of such period, the “Term”), unless either the SAB Member or RXi terminate this
Agreement pursuant to Sections 4 or 6 hereof, or unless this Agreement is extended by the mutual
written agreement of the SAB Member and RXi.

     6. Termination; Effect of Termination.

               (A) Termination by RXi for Cause. RXi may terminate this Agreement (in addition to any other
available remedy) at any time for Cause. The term “Cause” shall mean the SAB Member’s
material failure to perform his duties under this Agreement which goes uncured for more than 15
days following written notice from RXi, the SAB Member’s conviction of or plea of no contest to any
felony, or the SAB Member’s act or failure to act that materially and adversely affects the
business of RXi. If RXi terminates for Cause, the SAB Member will receive no further Options under
this Agreement.

               (B) Termination by SAB Member for Good Reason. The SAB Member may terminate this Agreement
(in addition to any other available remedy) at any time for Good Reason. The term “Good
Reason” shall mean (i) RXi’s breach of any of its material obligations under this Agreement in
any material respect (including without limitation, RXi’s payment obligations and RXi’s obligations
with respect to the Options and the Option Shares) if such breach is not cured within 15 days (10
days in the case of a breach of a payment obligation) after receipt by such party of written notice
thereof, or (ii) the occurrence any of the following events upon not less than 15 days prior
written notice to RXi at any time after the occurrence of such events, but in no event later than
60 days after written notice from RXi to the SAB Member of the occurrence of any of such events:

	 	•	 	a decree, judgment, or order by a court of competent jurisdiction shall have been
entered adjudging RXi as bankrupt or insolvent, or approving as properly filed a
petition seeking reorganization of RXi under any bankruptcy or similar law, and such
decree of order shall have continued undischarged and unstayed for a period of 60 days;
or a decree or order of a court of competent jurisdiction ordering the appointment of a
receiver, liquidator, trustee, or assignee in bankruptcy or insolvency of RXi, or for
the winding up or liquidation of the affairs of RXi, shall

-5-

 

	 	 	 	have been entered, and such decree, judgment, or order shall have remained in force
undischarged and unstayed for a period of 60 days;

	 	•	 	RXi shall institute proceedings to be adjudicated a voluntary bankrupt, or shall
consent to the filing of a bankruptcy proceeding against it, or shall file a petition
or answer or consent seeking reorganization under any bankruptcy or similar law or
similar statute, or shall consent to the filing of any such petition, or shall consent
to the appointment of a custodian, receiver, liquidator, trustee, or assignee in
bankruptcy or insolvency of it or any of its assets or property, or shall make a
general assignment for the benefit of creditors, or shall admit in writing its
inability to pay its debts generally as they become due; or
	 
	 	•	 	RXi and its affiliates shall discontinue or suspend indefinitely substantially all
research and development efforts in the Field.

If the SAB Member terminates for Good Reason, the Granting Party shall remain obligated to grant
all Options under this Agreement required pursuant to Section 3(A)(2) hereof at the times and with
the terms specified hereunder.

               (C) Termination by RXi without Cause; termination by SAB Member without Good Reason. RXi or
the SAB Member may terminate this Agreement at any time without cause and without liability to any
other party upon at least 90 days prior written notice to RXi or the SAB Member, as the case may
be. If RXi terminates this Agreement without Cause, the Granting Party shall remain obligated to
grant all Options under this Agreement required pursuant to Section 3(A)(2) hereof at the times and
under the terms specified hereunder. If the SAB Member terminates this Agreement without Good
Reason, he will receive no further Options under this Agreement; provided that, if the SAB Member
terminates this Agreement pursuant to this Section following the first, second or third anniversary
of the Effective Date but prior to the time that RXi has granted the SAB Member the Option with
respect to such anniversary, then RXi shall remain obligated to grant the Option with respect to
such anniversary only.

               (D) Termination due to Death or Disability. This Agreement shall automatically terminate upon
the death of the SAB Member, or upon notice from RXi or the SAB Member following the
“Disability” of the SAB Member. For purposes of this Agreement, the SAB Member shall be
considered “to have suffered a Disability” if: (i) he is incapacitated or disabled by accident,
sickness or otherwise so as to render him mentally or physically incapable of performing a
substantial part of the Services, with or without reasonable accommodation, required to be
performed by him under this Agreement for a period of at least 90 consecutive days, or for 90 days
(whether or not consecutive) during any six (6) month period. A termination by death or Disability
shall not be considered a termination for Cause. Upon the SAB Member’s death or Disability, the
Granting Party shall remain obligated to grant all Options under this Agreement required pursuant
to Section 3(A)(2) hereof at the times and with the terms specified hereunder; provided that, in
the event of the death of the SAB Member, the Granting Party shall be entitled to rely on
instructions of the executor of the SAB Member’s estate, or any other party reasonably determined
by the Granting Party based on the advice of counsel to be the appropriate person to provide
instructions, with respect to the party to receive such grant and all other

-6-

 

matters in connection with such grant, and provided further, that the Granting Party’s
obligation to make such grants following the death of the SAB Member shall be subject to compliance
with federal and state securities laws.

               (E) Termination Pursuant to Section 4. Either party may terminate this Agreement at any time
subject to and in accordance with the provisions of Section 4. Upon the termination of this
Agreement pursuant to Section 4 (other than a termination by RXi that is treated under Section 4 as
a termination for Cause or a termination by the SAB Member other than for Good Reason), the
Granting Party shall remain obligated to grant all Options under this Agreement required pursuant
to Section 3(A)(2) hereof at the times and under the terms specified hereunder.

               (F) Survival of Certain Provisions. No termination of this Agreement shall relieve the SAB
Member or RXi of any obligations hereunder which by their terms are intended to survive the
termination of the SAB Member’s association with RXi, including, but not limited to, the
obligations of Sections 3 (as to only those provisions that are specifically described as being
applicable after the Term), 8, 9, 10, 11, 12, 15, 18, 19, and 22 through 24 hereof.

               (G) Return of RXi Property. Upon termination of this Agreement for any reason, the SAB Member
shall promptly deliver to RXi any and all property of RXi or their customers, licensees, licensors,
or affiliates provided to SAB Member pursuant to this Agreement which may be in his possession or
control, including without limitation, products, memoranda, notes, diskettes, records, reports,
laboratory notebooks, or other documents or photocopies of the same and shall destroy any
Confidential Information (as defined in Section 9 hereof) in tangible form.

               (H) Rights of Principal Institution. The termination of this Agreement shall not affect (i)
RXi’s obligations to recognize the priority of Institute and the University of Massachusetts
intellectual property rights under the third paragraph of Section 8 or RXi’s obligations to defend
and indemnify the Institute under Section 19.

     7. Independent Contractor. It is understood and agreed that the SAB Member is an
independent contractor and that neither this Agreement nor the Services to be rendered hereunder
shall for any purpose whatsoever or in any way or manner create any employer-employee relationship
between the parties. The SAB Member shall not be entitled to any fringe benefits generally
provided to employees of RXi and RXi shall not be required to maintain workers’ compensation
coverage for the SAB Member.

     8. Inventions. The SAB Member shall promptly disclose to RXi, and, subject to the
terms of the third paragraph of this Section 8, hereby assigns and agrees to assign to RXi (or as
otherwise directed by RXi), his full right, title and interest, if any, to all Inventions (as
defined below). The SAB Member agrees to cooperate fully with RXi, their attorneys and agents, in
the preparation and filing of all papers and other documents as may be required to perfect RXi’s
rights in and to any of such Inventions, including, but not limited to, execution of any and all
applications for domestic and foreign patents, copyrights or other proprietary rights and the
performance of such other acts (including, among others, the execution and delivery of instruments
of further assurance or confirmation) requested by RXi to assign the Inventions to

-7-

 

RXi and to permit RXi to file, obtain and enforce any patents, copyrights or other proprietary
rights in the Inventions, all at RXi’s sole cost and expense. The SAB Member hereby designates RXi
as his agent, and grants to RXi a power of attorney with full power of substitution, which power of
attorney shall be deemed coupled with an interest, for the purpose of effecting any such assignment
hereunder from the SAB Member to RXi in the event the SAB Member should fail or refuse to sign and
deliver any document in connection with perfecting the foregoing rights of RXi within 10 days
following RXi’s request; provided that, in each case in which RXi intend to exercise this right (i)
they shall give the SAB Member and the Institute 30 days written notice, by certified mail (the
Institute’s copy being mailed to the Office of the General Counsel, Howard Hughes Medical
Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815 Attn: General Counsel) that they intend
to exercise their rights under this sentence, which notice shall refer to this Agreement and shall
be accompanied by (a) copies of the documents that RXi intend to execute or file, or a description
of the other acts that Companies intend to take, and (b) reasonably sufficient information about
the Invention or other intellectual property to which the documents or acts relate for the SAB
Member and the Institute each to make a determination of whether the document or acts relate to an
Invention; and (ii) RXi may not exercise their rights under this sentence if either the SAB Member
or the Institute notifies RXi within the 30-day period referred to above that the SAB Member or the
Institute disagrees.

     “Inventions” shall mean, for purposes of this Section 8, ideas, discoveries,
creations, manuscripts and properties, innovations, improvements, know-how, inventions, trade
secrets, apparatus, developments, techniques, methods, biological processes, cell lines, laboratory
notebooks and formulas (whether or not patentable or copyrightable or constituting trade secrets)
conceived, made or discovered by the SAB Member (whether alone or with others) within the Field (i)
solely as a direct result of consulting with RXi under this Agreement and (ii) not in the course of
the SAB Member’s activities as an Institute employee or University of Massachusetts faculty member.

     RXi acknowledges and agrees that the SAB Member is bound by the UMass Provisions. In the
event of any inconsistency between the terms and provisions of this Section 8 and the UMass
Provisions, the UMass Provisions shall govern. In this respect, in no event shall the SAB Member’s
obligations hereunder relate to any right, title or interest that the SAB Member may have in ideas,
discoveries, creations, manuscripts and properties, innovations, improvements, know-how,
inventions, trade secrets, apparatus, developments, techniques, methods, biological processes, cell
lines, laboratory notebooks and formulas (whether or not patentable or copyrightable or
constituting trade secrets) conceived, made or discovered by the SAB Member (whether alone or with
others) with the use of facilities or fundings of any Affiliated Institution and that the SAB
Member is required to assign to his Affiliated Institution pursuant to the rules and regulations
of such Affiliated Institution. Further, RXi will have no rights by reason of this Agreement in
any publication, invention, discovery, improvement, or other intellectual property whatsoever,
whether or not publishable, patentable, or copyrightable, which is developed as a result of a
program of research financed, in whole or in part, by funds provided by or under the control of
either Principal Institution. The SAB Member agrees to not knowingly use or incorporate any third
party proprietary information into any Inventions or to disclose such information to RXi. Upon
termination of this Agreement with RXi, the SAB Member shall provide to RXi in writing a full,
signed statement of all Inventions in which the SAB Member participated prior to termination of
this Agreement.

-8-

 

     RXi acknowledges and agrees that it will enjoy no priority or advantage as a result of the
consultancy created by this Agreement in gaining access, whether by license or otherwise, to any
proprietary information or intellectual property that arises from any research undertaken by the
SAB Member in his capacity as an employee of the Institute or a member of the faculty of University
of Massachusetts.

     9. Confidentiality. The SAB Member may disclose to RXi any information that the SAB
Member would normally freely disclose to other members of the scientific community at large,
whether by publication, by presentation at seminars, or in informal scientific discussions.
However, the SAB Member shall not disclose to RXi information that is proprietary to the Institute
or the University of Massachusetts and is not generally available to the public other than through
formal technology transfer procedures.

     During the Term, the SAB Member will be exposed to certain information concerning RXi’s
research, business, Inventions, products, proposed new products, designs, clinical testing
programs, manufacturing processes and techniques, customers, and other information and materials
that embody trade secrets or technical or business information that is confidential and proprietary
to RXi and is not generally known to the public (collectively, “Confidential Information”).
Confidential Information shall not include information that (i) is in the public domain on the
Effective Date of this Agreement, (ii) is or was disclosed to the SAB Member by a third party
having no fiduciary relationship with RXi and having no known obligation of confidentiality with
respect to such information, (iii) is or was independently known or developed by the SAB Member
without reference to the Confidential Information as reasonably demonstrated by the SAB Member by
written records or (iv) is required by law or in a legal proceeding to be disclosed, provided that
the SAB Member shall give RXi prior written notice of such proposed disclosure so that RXi may take
such legal steps as they deem appropriate to protect the Confidential Information. In addition,
Confidential Information does not include information generated by the SAB Member, alone or with
others, unless the information (i) is generated solely as a direct result of the performance of the
Services and (ii) is not generated in the course of the SAB Member’s activities as an Institute
employee or University of Massachusetts faculty member. The SAB Member hereby agrees, for a period
of seven years following his receipt of such Confidential Information, not to disclose or make use
of, or allow others to use, any Confidential Information, except to RXi’s employees and
representatives, without RXi’s prior written consent, unless such information becomes publicly
available through no fault of the SAB Member; provided, however, that such obligations of the SAB
Member will expire no later than five years after the termination or expiration of this Agreement.
In addition, the SAB Member further agrees not to make any notes or memoranda relating to the
Business of RXi other than for the benefit of RXi and not to use or permit to be used at any time
any such notes or memoranda other than for the benefit of RXi.

     10. Injunctive Relief. The SAB Member agrees that any breach of this Agreement by him
could cause irreparable damage to RXi and that in the event of such breach RXi shall have the right
to obtain injunctive relief, including, without limitation, specific performance or other equitable
relief to prevent the violation of his obligations hereunder. It is expressly understood and
agreed that nothing herein contained shall be construed as prohibiting RXi from pursuing any other
remedies available for such breach or threatened breach, including, without limitation, the
recovery of damages by RXi.

-9-

 

     11. No Assignment by the SAB Member. The Services to be rendered by the SAB Member
are personal in nature. The SAB Member may not assign or transfer this Agreement or any of his
rights or obligations hereunder. In no event shall the SAB Member assign or delegate
responsibility for actual performance of the Services to any other natural person.

     12. Publications. The SAB Member agrees that he will not at any time during the time
limitations set forth in paragraph 9 hereof, publish any Confidential Information that becomes
known to him as a result of his relationship with RXi which is, or pursuant to the terms hereof
becomes, the property of RXi or any of its clients, customers, consultants, licensors, licensees,
or affiliates except to such extent as may be necessary in the ordinary course of performing in
good faith his duties as a member of the SAB of RXi and with the prior written consent of RXi.

     During the Term and for a period of two years thereafter, the SAB Member agrees to submit to
RXi for a period of at least 30 days (the “Review Period”) a copy of any proposed
manuscript or other materials to be published or otherwise publicly disclosed by the SAB Member
(each a “Proposed Publication”) which contains Confidential Information or discloses
Inventions in sufficient time to enable RXi to determine if patentable Inventions or Confidential
Information would be disclosed. Nothing herein shall be construed to restrict the SAB Member’s
right to publish material which does not contain Confidential Information. Following the
expiration of the Review Period, if RXi does not notify the SAB Member that the Proposed
Publication discloses patentable Inventions or Confidential Information such Proposed Publication
shall be deemed to be approved by RXi for publication. In addition, the SAB Member will cooperate
with RXi in this respect and will delete from the manuscript or other disclosure any Confidential
Information if requested by RXi and will assist RXi in filing for patent protection for any
patentable Inventions prior to publication or other disclosure.

     13. No Conflicting Agreements. The SAB Member represents and warrants, that as of the
Effective Date, he will not be a party to any commitments or obligations that conflict with this
Agreement. In this regard, as a condition to the effectiveness of this Agreement the SAB Member
shall obtain the University of Massachusetts’s execution of Exhibit A to this Agreement. During
the Term, the SAB Member will not enter into any agreement either written or oral in conflict with
this Agreement and will arrange to provide Services under this Agreement in such a manner and at
times that such Services will not conflict with his responsibilities under any other agreement,
arrangement or understanding or pursuant to any employment relationship he has at any time with any
third party. In the event of any inconsistency between this Agreement and any agreement or policy
of any Affiliated Institution, the agreement or policy of the Affiliated Institution shall
control.

     14. Other Consulting Services. RXi agrees that the SAB Member may serve as a member
of scientific advisory boards or in a similar capacity with, and provide consulting services to,
other companies in scientific areas outside of the Field, provided that such service does not
conflict or materially interfere with his Services hereunder. RXi further agrees that the SAB
Member may serve as a member of scientific advisory boards or in a similar capacity with, and
provide consulting services to, other companies in scientific areas within the Discovery Sub-Field
(defined below), provided that such service does not conflict or materially interfere with his
Services hereunder. For purposes hereof, the term “Discovery Sub-Field” shall mean that

-10-

 

portion of the Field that includes the use of RNAi technology in, or the application of RNAi
technology to, the discovery or identification of targets for therapeutic products for humans or
animals. RXi further agrees that the SAB Member shall be entitled to provide consulting services
to Shuanglian Therapeutics within the Field; provided, however, that such consent by RXi may be
withdrawn at any time, upon not less than 30 days written notice to the SAB Member, that RXi
determines, in its reasonable judgment, that such company is engaging in substantial business
activities in the Field outside of China and that such activities are reasonably likely to be
competitive with the activities of RXi. The SAB Member shall notify RXi in writing in advance of
such service, provided that RXi shall hold all such information in confidence, and provided further
that the SAB Member need not provide copies of any agreements with such other companies or any
information relating to his compensation for such services. The restrictions set forth in this
Section 14 shall not apply to the SAB Member’s relationship with the Institute or other Affiliated
Institutions.

     15. Nonsolicitation. During the Term and for a period of one year thereafter, the SAB
Member, personally, will not, without RXi’s prior written consent, directly solicit the employment
of any employee of RXi or their affiliates with whom the SAB Member has had contact in connection
with the relationship arising under this Agreement. Nothing in this Section 15 shall be deemed to
prohibit general solicitations of employment by any Affiliated Institution.

     16. Disclosure of Relationship. The parties each shall be entitled to disclose that
the SAB Member is serving on the SAB and RXi may use the SAB Member’s name and, in doing so may
cite the SAB Member’s relationship with the Institute, including in any business plan, press
release, advertisement, prospectus or other offering document of RXi or its affiliates, so long as
any such usage (a) is limited to reporting factual events or occurrences only, and (b) is made in a
manner that could not reasonably constitute a specific endorsement by the Institute or the SAB
Member of RXi or of any program, product or service of RXi. However, RXi shall not use the SAB
Member’s name or the Institute’s name in any press release, or quote the SAB Member in any RXi
materials (including advertisements), or otherwise use the SAB Member’s name or the Institute’s
name in a manner not specifically permitted by the preceding sentence, unless in each case RXi
obtains in advance the written consent of the Institute, and, in the case of the use of the SAB
Member’s name, the SAB Member’s consent as well. The foregoing consents shall not be unreasonably
withheld or delayed by the SAB Member. Notwithstanding the foregoing, if, in the opinion of RXi’s
counsel, RXi is required by applicable law to use the SAB Member’s name or the Institute’s name in
a press release or governmental filing and, under the circumstances, RXi is not reasonably able to
obtain the advance written consent of the Institute or the SAB Member, as applicable, to such use,
then RXi may proceed without obtaining the advance written consent of the Institute or the SAB
Member, as applicable.

     17. Notices. All notices and other communications hereunder shall be delivered or
sent by facsimile transmission, recognized courier service, registered or certified mail, return
receipt requested. Any notice or required submission of documents to RXi made under the provisions
of this Agreement shall be deemed to have been constructively delivered to Araios for purposes of
this Agreement.

-11-

 

If to RXi:

Tod Woolf

Chief Executive Officer

RXi Pharmaceuticals Corporation

One Innovation Drive

Worcester, Massachusetts 01605

Fax: 908-663-2642

with a copy to:

Ropes & Gray LLP

One International Place

Boston, MA 02110

Attention: Marc A. Rubenstein, Esq.

Fax: (617) 951-7050

If to the SAB Member:

Craig C. Mello, Ph.D.

Howard Hughes Medical Institute

University of Massachusetts

373 Plantation St., Suite 219

Worcester, MA 01605

Fax: (508) 856-2950

with a copy to:

Richard B. Weinstein, Esq.

6701 Democracy Blvd., Suite 300

Bethesda, MD 20817

Fax: (301) 571-9385

     Such notice or communication shall be deemed to have been given as of the date sent by the
facsimile or delivered to a recognized courier service, or three days following the date sent by
registered or certified mail.

     18. Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective legal representatives, successors and permitted
assigns. The SAB Member agrees that RXi may assign this Agreement, in whole but not in part, to
any purchaser of all or substantially all of its assets or to any successor corporation resulting
from any merger, consolidation or other reorganization of RXi with or into such corporations. RXi
also may assign this Agreement, in whole but not in part, to any person or entity controlled by, in
control of, or under common control with, RXi, if it obtains the prior written consent of the SAB
Member, which consent shall not unreasonably be withheld or delayed; provided, however, that

-12-

 

no such assignment shall relieve RXi of its liability to the SAB Member hereunder; and
provided further, however, that no such assignment shall be made to CytRx or any affiliate thereof
without the prior written consent of the SAB Member, which consent he may withhold in his sole and
unfettered discretion. Notwithstanding the foregoing, RXi may not enter into any transaction
pursuant to which all or substantially all of its assets or shares are acquired by a third party,
or it merges with any third party unless, in any such transaction, such third party explicitly
assumes, in writing, all of RXi’s obligations and the obligations of the “Granting Party” under
this Agreement. RXi may not otherwise assign this Agreement without the SAB Member’s prior written
consent.

     19. Indemnification. RXi shall indemnify, defend and hold harmless the SAB Member
from any claim, loss, liability or expense (including reasonable attorney’s fees) incurred by him
as a result of the performance of his Services hereunder in accordance with the terms hereof, a
material breach by RXi hereof or any gross negligence or willful misconduct by RXi or its
respective officers or directors in connection with this Agreement or otherwise relating to or
resulting from the performance of the Services hereunder, except where such claim, loss, liability
or expense is attributable primarily to the SAB Member’s own gross negligence or willful
misconduct.

     RXi agrees, at its sole expense, to defend the Institute against, and to indemnify and hold
the Institute harmless from, any liability, claim, judgment, cost, expense, damage, deficiency,
loss, or obligation, of any kind or nature (including without limitation reasonable attorneys’ fees
and other costs and expenses of defense) relating to a claim or suit by a third party against the
Institute, either arising from this Agreement, the SAB Member’s performance of Services, or any
products or services of RXi which result from the SAB Member’s performance of Services.

     20. Entire Agreement; Counterparts. This Agreement constitutes the entire agreement
among the parties as to the subject matter hereof. No provision of this Agreement shall be waived,
altered or cancelled except in writing signed by the party against whom such waiver, alteration or
cancellation is asserted. RXi and the SAB Member acknowledge and agree that any amendment of this
Agreement (including, without limitation, any extension of this Agreement or any change from the
terms of Section 3 in the consideration to be provided to the SAB Member with respect to the
Services) or any departure from the terms or conditions hereof with respect to the SAB Member’s
consulting services for RXi is subject to the Institute’s prior written approval. Any such waiver
shall be limited to the particular instance and the particular time when and for which it is given.
This Agreement may be executed in one or more counterparts, and by different parties hereto on
separate counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

     21. Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Delaware, without regard to conflict of law principles.

     22. Enforceability. The invalidity or unenforceability of any provision hereof as to
an obligation of a party shall in no way affect the validity or enforceability of any other
provision of this Agreement, provided that if such invalidity or unenforceability materially
adversely affects the benefits the other party reasonably expected to receive hereunder, that party
shall

-13-

 

have the right to terminate this Agreement. Moreover, if one or more of the provisions
contained in this Agreement shall for any reason be held to be excessively broad as to scope,
activity or subject so as to be unenforceable at law, such provision or provisions shall be
construed by limiting or reducing it or them, so as to be enforceable to the extent compatible with
the applicable law as it shall then appear. Notwithstanding any other provision of this Section 22
to the contrary, if any provision of this Agreement affecting the rights or property of the
Institute is adjudicated to be invalid, unenforceable, contrary to, or prohibited under applicable
laws or regulations of any jurisdiction, this Agreement shall terminate as of the date such
adjudication is effective.

     23. Construction. This Agreement has been prepared jointly and shall not be strictly
construed against any party.

     24. Resolution of Disputes. Except as set forth below, any dispute arising under or
in connection with any matter related to this Agreement or any related agreement shall be resolved
exclusively by arbitration. The arbitration will be in conformity with and subject to the
applicable rules and procedures of the American Arbitration Association. All parties agree to be
(i) subject to the jurisdiction and venue of any arbitration or litigation in Boston,
Massachusetts; and (ii) bound by the decision of the arbitrator as the final decision with respect
to any dispute that is to be resolved by arbitration pursuant to this Agreement. Notwithstanding
the foregoing, any dispute or controversy that involves the rights of the Institute shall not be
determined by arbitration.

     25. Advice of Counsel. Each party acknowledges that, in executing this Agreement,
such party has had the opportunity to seek the advice of independent legal counsel, and has read
and understood all of the terms and provisions of this Agreement.

     26. Individual Capacity; Third Party Beneficiary. The SAB Member and RXi acknowledge
that (i) the SAB Member is entering into this Agreement in his individual capacity and not as an
employee or agent of the Institute, (ii) the Institute is not a party to this Agreement and has no
liability or obligation hereunder, and (iii) the Institute is an intended third-party beneficiary
of this Agreement and certain provisions of this Agreement (excluding the compensation provisions
of Section 3(A), (B), and (D)) are for the benefit of the Institute and are enforceable by the
Institute in its own name.

-14-

 

     IN WITNESS WHEREOF, the parties hereto have duly executed this Scientific Advisory Board
Agreement as a sealed instrument as of the date first written above.

	 	 	 	 	 
	 	RXI PHARMACEUTICALS CORPORATION

 	 
	 	By:  	/s/
Tod Woolf	 
	 	 	Tod Woolf 	 
	 	 	Chief Executive Officer 	 
	 

	 	 	 	 	 
	SAB MEMBER

 	 	 
	/s/
Craig
C. Mello	 	 
	Name:  	Craig C. Mello, Ph.D. 	 	 
	 	 	 
	Social Security Number:

 	 	 
	 	 	 
	 
	Effective Date:   ___________, 2007 	 	 
	 	 	 

-15-

 

	 	 	 	 	 

Page A1

SCHEDULE A

Conflicting Agreements

UNIVERSITY OF MASSACHUSETTS

UNIFORM CONSULTING AGREEMENT PROVISIONS

AS MODIFIED FOR HHMI INVESTIGATORS

All faculty at the University of Massachusetts (the “University”), including faculty who are
employees of the Howard Hughes Medical Institute (“HHMI”) pursuant to the Collaboration Agreement
between HHMI and the University, are subject to the University Policy on Faculty Consulting and
Outside Activities (the ‘Policy”). The Policy recommends that faculty at the University attach
these Uniform Consulting Agreement Provisions (“Uniform Provisions”) to any agreement or
arrangement (“Consulting Agreement”) under which a faculty member will provide consulting services
to, or will engage in other non-academic activities in his or her area of expertise on behalf of
any for-profit organization (a “Company”). These Uniform Provisions are intended to clarify, among
other things, the respective legal rights of the University and the Company in any intellectual
property and other work product that may be developed or discovered by the faculty member in the
course of performing services for the Company. If any term of the Uniform Provisions is
inconsistent with a term of the Consulting Agreement to which the Uniform Provisions are attached,
the terms of the Uniform Provisions govern.

University faculty are permitted to devote the equivalent of one day within the academic week to
the performance of outside activities, including consulting with Companies. These activities must
be reported to the Department Chair of the faculty member in order to ensure compliance with this
time restriction and the ability of the faculty member to meet his or her responsibilities to the
University. In certain instances, these activities must also be reviewed by the University’s
Conflicts Committee. The Conflicts Committee may impose restrictions on the consulting
relationship.

University faculty are ordinarily prohibited from using University-administered funds, facilities,
and equipment in the performance of services for a Company pursuant to a Consulting Agreement. In
addition, faculty must obtain special approval to involve University students in consulting or
other services for Companies. Companies may obtain access to University facilities, equipment, and
personnel under a sponsored research agreement with the University.

University faculty may not use the name of the University in relation to any outside activities,
including consulting work, except to describe their credentials.

University faculty are permitted to assign to a Company their rights in any invention, discovery,
or development (collectively, “Intellectual Property”) that arises while performing services under
a Consulting Agreement, provided that the faculty member did not use University-administered funds,
facilities, or equipment (collectively, “University Resources”) in the course of developing that
Intellectual Property. If a faculty member made significant use of University Resources, the
faculty member is contractually obligated to assign to the University all of his or her rights in
that Intellectual Property (unless the faculty member is an HHMI employee, in which case the

 

 

Page A2

faculty member assigns Intellectual Property to HHMI, and HHMI assigns Intellectual Property to the
University, in accordance with the Collaboration Agreement).

The University presumes that a faculty member did make significant use of University Resources in
the development of Intellectual Property that is the same as, directly related to, or substantially
similar to a research project in which that faculty member is engaged at the University. In order
to avoid any confusion regarding ownership of Intellectual Property, the University has determined
and Company agrees that the field of services to be provided under this Consulting Agreement is
directly related to or substantially similar to the research projects undertaken by the faculty
member at the University. Therefore, any Intellectual Property developed by the faculty member
during the term of this Consulting Agreement, following assignment to HHMI to the University, is
owned by the University, and the Company may enter into negotiations to obtain license rights to
the Intellectual Property.

No Consulting Agreement may limit the ability of a University faculty member to use or publish
information that (a) was developed, discovered, or acquired by the faculty member in the course of
research performed at the University or otherwise outside the scope of the consulting services, (b)
was in the public domain before the consulting services were performed (c) entered the public
domain by means other than an unauthorized disclosure resulting from an act or omission by the
faculty member, (d) was known to the faculty member or the University before the consulting
services were performed, or (e) is required to be disclosed in order to comply with applicable law,
regulations, or a court order.

A Company may require a faculty member to leave with the Company any notes, data, and records
developed in the performance of consulting services, provided that the faculty member may retain
one copy of those documents for archival purposes.

Companies should be aware that, in addition to the Policy, University faculty are subject to the
University Intellectual Property Policy and the University Policy on Conflicts of Interest Relating
to Intellectual Property and Commercial Ventures. The University will make the three policies
available upon request.

 

 

Page A3

These Uniform Provisions remain in effect during the entire term of the Consulting Agreement to
which they are attached.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AGREED AND ACCEPTED:	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Faculty Member	 	 	 	 	 	RXi
Pharmaceuticals Corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:
	 	/s/ Craig C. Mello	 	 	 	By:	 	/s/ Tod Woolf	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	Printed Name: 	Craig
C. Mello	 	 	 	 	 	Printed Name: 	 	 	 
	 
	 	Date:	2/16/07	 	 	 	 	 	Title:	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	Date:	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	University of
Massachusetts	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:
	 	/s/ Richard Stanton	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Printed Name: 	Richard Stanton	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Title:	Deputy
Chancellor	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Date:	2/20/07	 	 	 	 	 	 	 	 	 	 	 	 

 

 

RXi Pharmaceuticals Corporation

One Innovation Drive

Worcester, MA 10605

April 30, 2007

Craig C. Mello, Ph.D.

University of Massachusetts Medical School

373 Plantation Street, Suite 219

Worcester, MA 01605

Re: Scientific Advisory Board Agreement
between Craig C. Mello, Ph.D. and RXi Pharmaceuticals Corporation dated as of February 26, 2007 (the “Agreement”)

Dear Dr. Mello:

     We
are writing to confirm our mutual understanding concerning certain matters in connection
with the above-referenced Agreement.  Capitalized terms used but not defined in this letter
shall have the meaning given them in the Agreement.  We agree as follows:

     
RXi shall, as additional consideration for your services to be rendered under the
Agreement, at the first regularly scheduled meeting of the Board of Directors of RXi
following the Effective Date, grant to you an option (the “Additional Option”) to
purchase a number of shares equal to 1/280th of the number of shares of common stock of RXi
held by CytRx immediately prior to the Equity Funding.  The Additional Option shall have a
per share exercise price equal to the price per share paid for RXi stock in the Equity
Funding, shall have a ten year term from the date of grant and shall be exercisable in
full from and after the day before the fifth anniversary of the Effective Date (the “Vesting
Date”), provided that prior to the Vesting Date you have not terminated the Agreement
without Good Reason and RXi has not terminated the Agreement for Cause prior to the
Vesting Date.  Except as set forth in the preceding sentence regarding termination by
RXi for Cause and termination by you without Good Reason prior to the Vesting Date, the
Additional Option shall remain outstanding and shall continue to vest on the Vesting
Date notwithstanding any prior termination of the Agreement or your consulting
relationship with the RXi.  For purposes hereof:  (i) the failure of RXi to offer,
by notice to you given prior to the end of the initial four year term of the Agreement,
to extend the Agreement for an additional period of one year following the initial four
year Term on terms at least as favorable as are currently set forth in the Agreement
shall be deemed to be a termination by RXi without Cause (which shall cause the Additional
Option to remain outstanding and continue to vest on the Vesting Date); and (ii) the failure
of you to accept RXi’s offer to extend the Agreement for an additional period of
one year following the initial four year Term on terms at least as favorable as are
currently set forth in the Agreement shall be deemed to be a termination by you without
Good Reason (which shall cause the Additional Option to lapse).  From and after 

 

 

the Vesting Date, the Additional
Option shall not be subject to lapse for any reason (including, without limitation, a
subsequent termination for Cause or termination without Good Reason) prior to the end of
the 10 year term.  The Additional Option will otherwise be on such terms as set forth in
the standard form of RXi’s nonqualified stock option agreement.  The terms
of Section 3(A)(2) of the Agreement shall apply to the Additional Option to the extent
not inconsistent with the terms of this paragraph.

     In
addition, RXi will pay to you $10,000 within thirty (30) days following the Equity Funding,
in addition to the compensation set forth in the Agreement.

     
If you are in agreement with the foregoing, please countersign this letter where indicated
below and return it to the undersigned at your earliest convenience.

	 	 	 	 	 
	 	Very truly yours,

RXI PHARMACEUTICALS CORPORATION

 	 
	 	By:  	/s/
Tod Woolf  4/30/07	 

	 	 	 	 	 
	 
	AGREED:

 	 	 
	 Craig C. Mello, Ph.D.	 	 
	 
	/s/ Craig C. Mello	 	 
	 	 	 
	 
	Date: 4/30/2007exv10w29

 

Exhibit 10.29

December 27, 2007

Tod Woolf, Ph.D.

Chief Executive Officer

RXi Pharmaceuticals Corporation

60 Prescott Street

Worchester, MA 01605

     Re:     Reimbursement Agreement

Dear Tod:

     This letter sets forth the agreement (this “Agreement”) between CytRx Corporation (“CytRx”)
and RXi Pharmaceuticals Corporation (“RXi”), each a Delaware corporation, with respect to certain
fees and expenses incurred by the parties in connection with the following (collectively, the
“Subject Work”): (i) preparation and filing by RXi with the Securities and Exchange Commission
(“SEC”) of the Registration Statement on Form S-1 (Registration No. 333-147009), and all amendments
thereto (as amended, the “Registration Statement”); (ii) responding to SEC comments on the
Registration Statement; (iii) obtaining SEC effectiveness of the Registration Statement; (iv)
preparing and amending a confidential treatment request covering documents filed as exhibits to the
Registration Statement; (v) preparing and amending an application to have RXi’s common stock listed
on Nasdaq; and (vi) the distribution of shares of RXi common stock pursuant to the Registration
Statement.

     Because CytRx and RXi acknowledge and agree that the Subject Work will benefit both parties,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
CytRx and RXi agree as follows:

     1.     Payment of Fees and Expenses. Each of CytRx and RXi will bear and pay its own fees
and expenses incurred in connection with the Subject Work, subject to its right to be reimbursed by
the other for certain of such fees and expenses as provided below.

     2.     Reimbursement of Certain RXi Fees. CytRx will reimburse RXi an amount equal to 50%
of the total fees and expenses paid by RXi to Bowne & Co., Inc., Computershare Limited, and Ropes &
Gray LLP, in each case, to the extent such fees and expenses are directly attributable and
primarily related to the Subject Work.

     3.     Reimbursement of Certain CytRx Fees. RXi will reimburse CytRx an amount equal to
the sum of (i) $30,000 plus (ii) 50% of the total fees and expenses paid by CytRx to BDO Seidman,
LLP, Sanli Pastore & Hill, Inc., and John Branch, in each case, to the extent such fees and
expenses are directly attributable and primarily related to the Subject Work.

     4.     Initial Net Reimbursement Payment. On or before the date five days following the
distribution date of CytRx’s shares of RXi common stock pursuant to the Registration Statement,
CytRx and RXi will mutually determine as of the most recent practicable date the respective
reimbursement amounts due to and from each of them under paragraphs 2 and 3 above based on
reasonable documentation of such expenses, and CytRx or RXi, as the case may be, shall pay to the
other the net reimbursement amount due in accordance with the parties’ determination. If the net
reimbursement amount is not paid by the applicable party within the five day period, the amount
shall bear interest at the rate of 1.5% per month (or portion thereof) until paid.

     5.     Subsequent Reimbursement Payments. Following the payment described in paragraph 4
above, all reimbursements under this Agreement shall be paid by CytRx and RXi within 30 calendar
days

 

 

after notice from CytRx or RXi, as the case may be, to the other that it has paid amounts that
are reimbursable to it pursuant to paragraph 2 or paragraph 3 of this Agreement, which notice
shall be accompanied by reasonable documentation of the nature and amount of such payments.

     6.     Notices. All notices and other communications required or permitted to be given
hereunder shall be in writing and shall be deemed to have been duly given if delivered personally,
mailed by certified mail (return receipt requested) or sent by overnight delivery service or
facsimile transmission to the parties at the following addresses or at such other addresses as
shall be specified by the parties by like notice:

	 	 	 	 	 
	 

	 	If to Cytrx:
	 	CytRx Corporation

11726 San Vicente Boulevard, Suite 650

Los Angeles, CA 90049

Attention: President and Chief Executive Officer

Fax: (310) 826-6139
	 
	 	 	 	 
	 

	 	If to RXi:
	 	RXi Pharmaceuticals, Inc.

One Innovation Drive

Worcester, MA 01605

Attention: Chief Executive Officer

Fax: (508) 767-3862

     7.     Governing Law. This Agreement shall be governed by and be constructed in accordance
with the laws of the State of New York without regard to the conflict of laws provisions thereof.

     8.     Successors and Assigns. This Agreement shall inure to the benefit of and shall be
binding upon the successors and assigns of the parties hereto.

     9.     Complete Agreement. This Agreement sets forth the entire agreement and
understanding between the parties hereto with respect to the subject matter hereof. This Agreement
may not be changed, altered, modified or amended in any respect, except in a writing signed by the
parties hereto.

     10.     Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     11.     Attorney’s Fees. In the event of any litigation or other legal proceeding arising
out of or related to this Agreement, the prevailing party shall be entitled to recover from the
other party its reasonable attorneys’ fees and costs.

     If the above correctly reflects your agreement with respect to the foregoing matters, please
so confirm by signing the acknowledgement below and returning a copy of this letter to me.

	 	 	 	 	 
	 	Very truly yours,

CytRx Corporation

 	 
	 	By:  	                                              /s/ Steven A. Kriegsman
 	 
	 	 	Steven A. Kriegsman 	 
	 	 	President and Chief Executive Officer 	 
	 

Accepted and agreed to as of

the first date above written:

	 	 	 	 	 	 
	 	RXi Pharmaceuticals Corporation

 	 
	 	By:  	/s/ Tod Woolf	 
	 	 	Tod Woolf, Ph.D. 	 
	 	 	Chief Executive Officer 	 
	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]